Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

"AI can help clinicians translate unprecedented biological and clinical complexity into actionable insights," Robert L. Ferris, MD, PhD.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.